Welcome to Markets Desk, your midday read on what's moving.
Vertex Pharmaceuticals is making a major move into endocrinology, agreeing to acquire Crinetics Pharmaceuticals for eighty-five dollars a share in cash, valuing the deal at roughly ten billion dollars. Crinetics shares are surging on the news, reflecting a substantial premium, as Vertex looks to diversify well beyond its cystic fibrosis franchise.
Shifting to energy markets, Ukraine's military struck Russia's Omsk oil refinery overnight using long-range drones that traveled approximately seventeen hundred miles into Siberia — the deepest strike of the war so far. Footage confirmed fires at a key processing unit of what is Russia's largest refinery, a development that traders will be watching closely for any ripple into global crude supply expectations.
On the equity side, European markets are pointing flat to marginally lower at the open, with sentiment weighed down by persistent skepticism around artificial intelligence valuations. Meanwhile, Berkshire Hathaway's incoming chief Greg Abel has been quietly adding to the conglomerate's position in Alphabet, a stock that has doubled over the past year, signaling that Buffett's successor is comfortable leaning into the AI theme through established mega-cap names.
That's the tape. Markets Desk, signing off the floor.
